Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial
Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
The RheumNow faculty reporters have been scouring the meeting and online presentations to find the best abstracts from ACR22. Here are some of their choice abstracts reported today on day 1 of ACR 2022 (#ACRbest).
Dr. John Cush RheumNow
3 years 1 month ago
Join us for our daily topic panels--we'll be live on Twitter, LinkedIn, FB and YouTube OR sign up directly below.
https://t.co/lZK8vsySiD https://t.co/smUveqf3C6
It’s widely accepted that Psoriatic disease has multi-system, multi-domain potential that can lead to life altering complications if left untreated or undertreated. Rheumatologists have shifted the way we discuss treatment options and disease state expectations with patients. Two #ACR22 abstracts stood out to me regarding the Psoriatic disease patient experience and will, ultimately, add to what I do in clinic.
Catherine Sims, MD DrCassySims
3 years 1 month ago
What if my #myositis patient gets pregnant?
Abstract #0952 #ACR22 @RheumNow
🫁10 pregnancies ➡️ 1 miscarriage
-2 preterm
-3 low birth wght
-1 HELLP
-Mean gestational age 36w
🫁 Higher disease activity ➡️ more adverse pregnancy outcomes
Dr. Rachel Tate uptoTate
3 years 1 month ago
Application of 2022 adult-based AAV ACR/EULAR classification criteria to a large cohort of pediatric vasculitis patients resulted in different classification of one-third of patients compared to the EMA classification algorithm. Abs 0456 #ACR22 @RheumNow https://t.co/AWk4RijJLP https://t.co/nX96xTf7KW
Dr. Rachel Tate uptoTate
3 years 1 month ago
JAKi appear to be an effective and safety therapy in refractory GCA to cDMARDs and/or bDMARDs. Abs 0464 #ACR22 @RheumNow https://t.co/0ZjI8uTgnY https://t.co/OgxND7HrXj
Dr. Rachel Tate uptoTate
3 years 1 month ago
Mortality increased by 50% in GCA pts compared to matched controls during first year of follow up after dx. Main cause of this early excess mortality appears to be CVD. Abs 0467 #ACR22 @RheumNow https://t.co/TEV0qSlJuQ https://t.co/U8gv2SXhdQ
Dr. Rachel Tate uptoTate
3 years 1 month ago
Death rate is higher in the first year after AAV diagnosis and remains elevated in long-term follow up. Primary cause of death is the vasculitis itself. Abs 0448 #ACR22 @RheumNow https://t.co/z7qBnefTbR https://t.co/PRaUeK2XXd
David Liew drdavidliew
3 years 1 month ago
@alberta_hoi @RheumNow @seminarthrheum Indeed! Thanks Alberta
I think:
- they're not as separate as some might think
- it's possible beta-blockers could prevent damage-related remodelling
- at the least, couldn't they be additive?
Whatever the case, if it's real I want to use it. Big signal needs testing? #ACR22
Dr. Rachel Tate uptoTate
3 years 1 month ago
International survey finds induction therapy patterns for severe ANCA-associated vasculitis differ based on physician specialty, expertise, and practice setting. Abs 0442 #ACR22 @RheumNow https://t.co/gB6QhYnbp5 https://t.co/Io2hA9EZiW
Patricia Harkins DrTrishHarkins
3 years 1 month ago
🦵Heel enthesitis on physical exam predictive of ⬇️ likelihood of low disease activity and ⬆️ scores in Global VAS, BASDAI, ASDAS and BASFI on 2yr follow up in r-axSpA
# The Achilles heel of r-axSpA!
Abst#0375
#ACR22 @RheumNow
Poster Hall